Global Digital Signature Market to Reach $2,934.6 Million by 2023     |    Global Outdoor Lighting Market to Witness 8.4% CAGR during 2017 - 2023     |    Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

Systemic Lupus Erythematosus Pipeline Analysis

P&S Market Research-Systemic Lupus Erythematosus Pipeline Analysis report

Systemic Lupus Erythematosus Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: May 2017
Report Code: LS10944
Available Format: pdf
Pages: 172

Pipeline Overview

Systemic lupus erythematosus is a chronic inflammatory disease that involves swelling and pain, most commonly on face. The disease affects many parts of the body including skin, joints, kidneys, pleura, pericardium and brain. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. As of now there is no cure for systemic lupus erythematosus, but medical interventions and lifestyle changes can help in improving quality of life. The systemic lupus erythematosus can be mild to severe in its form. The cause of systemic lupus erythematosus is unknown, but it is most likely linked to genetic, environmental and hormonal factors. The chance of developing systemic lupus erythematosus is 10 times greater in women as compared to men.

Systemic lupus erythematosus includes symptoms such as oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is diagnosed by examining the symptoms, physical examination, X-rays and lab tests.

Systemic lupus erythematosus treatment involves a combination approach as number of organs are involved. The treatment consists immunosuppressive drugs that inhibit activity of the immune system. The most common approach to treat systemic lupus erythematosus is the use of hydroxychloroquine and corticosteroids including prednisone.

Pipeline Analysis

As of April 2017, the systemic lupus erythematosus pipeline comprises of approximately 57 active drug candidates, out of which four drug candidates are in Phase III stage, 21 drug candidates are in Phase II stage, 20 drug candidates are in Phase I stage, 11 drug candidates are in Pre-Clinical stage and one drug candidates is in the Discovery stage.
Pharmaceutical companies such as Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA, Eli Lilly and Company, Janssen Research & Development, LLC, Redx Pharma plc and AstraZeneca plc are actively involved in the development of systemic lupus erythematosus pipeline. Anifrolumab is being developed by AstraZeneca plc, in Phase III clinical stage for the treatment of systemic lupus erythematosus. It is a monoclonal antibody being developed to be administered by intravenous route and inhibit the activity of all type I interferons including IFN-α, IFN-β and IFN-ω.

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

Competitive Landscape

Several companies are involved in the development of systemic lupus erythematosus pipeline, with their products in different phases. Anthera Pharmaceuticals, Inc. and AstraZeneca plc have their drug candidates in the Phase III stage of development. Janssen Research & Development, LLC has three drug candidates out of which one is in Phase II stage of development and two are in Phase I stage of development. Merck KGaA also has two drug candidates in Phase II stage of development. Redx Pharma plc has two drug candidates in Pre-Clinical stage of development.

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA, Eli Lilly and Company, Janssen Research & Development, LLC, Redx Pharma plc and AstraZeneca plc.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

2500
Group License

Group License authorizes access of the publication upto 5 users.

3250
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

4750
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

7000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment